Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 13/20 | 0.60 |
| ▸ | ESR2 known ✓ | Q92731 | 13/20 | 0.60 |
| ▸ | TOP1 known ✓ | P11387 | 2/20 | 0.60 |
| ▸ | HDAC1 known ✓ | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC2 known ✓ | Q92769 | 2/20 | 0.36 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | HRAS | P01112 | 14/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7505217 | 0.99 | KDM4E (0.60) | KDM4EPOLBMAPTHIF1AHRAS | |
| Hydrochloric Acid SCHEMBL7507048 | 0.99 | KDM4E (0.60) | KDM4EPOLBMAPTHIF1AHRAS | |
| SCHEMBL3685005 | 0.99 | HRAS (0.61) | KDM4EPOLBMAPTHIF1AHRAS | |
| SCHEMBL7503370 | 0.99 | HRAS (0.61) | KDM4EPOLBMAPTHIF1AHRAS | |
| SCHEMBL7510696 | 0.98 | HRAS (0.60) | KDM4EPOLBMAPTHIF1AHRAS | |
| SCHEMBL7506162 | 0.98 | HRAS (0.60) | KDM4EPOLBMAPTHIF1AHRAS | |
| SCHEMBL7504933 | 0.98 | HRAS (0.60) | KDM4EPOLBMAPTHIF1AHRAS | |
| SCHEMBL7498136 | 0.98 | HRAS (0.60) | KDM4EPOLBMAPTHIF1AHRAS | |
| SCHEMBL7501006 | 0.98 | HRAS (0.60) | KDM4EPOLBMAPTHIF1AHRAS | |
| SCHEMBL7507423 | 0.98 | HRAS (0.60) | KDM4EPOLBMAPTHIF1AHRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642229-B2 | Pharmaceutical composition and a product which includes a substituted acryloyl distamycin derivative, an antimicrotubule agent and/or an antimetabolite | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-01-05 | — | — | US | claimed |
| US-20090074757-A1 | Antitumor Combination Comprising Substituted Acryloyl Distamycin Derivatives and Antibodies Inhibiting Growth Factors or Their Receptors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-03-19 | — | — | US | claimed |
| EP-1299110-B1 | COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES AND ANTIMETABOLITES | NERVIANO MEDICAL SCIENCES SRL (IT) | 2008-11-26 | — | — | EP | claimed |
| EP-1889624-A2 | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2008-02-20 | — | — | EP | claimed |
| EP-1461083-B1 | COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES AND PROTEIN KINASE (SERINE/THREONINE KINASE) INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2006-03-29 | — | — | EP | claimed |
| EP-1461083-A1 | COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES AND PROTEIN KINASE (SERINE/THREONINE KINASE) INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-09-29 | — | — | EP | claimed |
| US-20040092453-A1 | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2004-05-13 | — | — | US | claimed |
| US-20030180383-A1 | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2003-09-25 | — | — | US | claimed |
| US-20030162722-A1 | Pharmaceutical compositions comprising acryloyl distamycin derivatives and topoisomerase I and II inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2003-08-28 | — | — | US | claimed |
| WO-2003055522-A1 | COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES AND PROTEIN KINASE (SERINE/THREONINE KINASE) INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2003-07-10 | — | — | WO | claimed |
| EP-1303307-A2 | COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES AND ALKYLATING AGENTS | Pharmacia Italia S.p.A. (IT) | 2003-04-23 | — | — | EP | claimed |
| EP-1299110-A2 | COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES, TAXANES AND/OR ANTIMETABOLITES | Pharmacia Italia S.p.A. (IT) | 2003-04-09 | — | — | EP | claimed |
| EP-1292290-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING ACRYLOYL DISTAMYCIN DERIVATIVES AND TOPOISOMERASE I AND II INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2003-03-19 | — | — | EP | claimed |
| WO-2001097790-A2 | COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES AND ALKYLATING AGENTS | PHARMACIA ITALIA S.P.A. (IT) | 2001-12-27 | — | — | WO | claimed |
| WO-2001097789-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING ACRYLOYL DISTAMYCIN DERIVATIVES AND TOPOISOMERASE I AND II INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2001-12-27 | — | — | WO | claimed |
| WO-2001097618-A2 | COMBINED THERAPY AGAINST TUMORS COMPRISING SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES, TAXANES AND/OR ANTIMETABOLITES | PHARMACIA ITALIA S.P.A. (IT) | 2001-12-27 | — | — | WO | claimed |
| US-8642580-B2 | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and platinum derivatives | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-02-04 | — | — | US | disclosed |
| EP-1889624-B1 | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites | NERVIANO MEDICAL SCIENCES SRL (IT) | 2010-12-15 | — | — | EP | disclosed |
| EP-1280527-A2 | USE OF SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES IN THE TREATMENT OF TUMORS ASSOCIATED WITH HIGH LEVELS OF GLUTATHIONE | Pharmacia Italia S.p.A. (IT) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001085144-A2 | USE OF SUBSTITUTED ACRYLOYL DISTAMYCIN DERIVATIVES IN THE TREATMENT OF TUMORS ASSOCIATED WITH HIGH LEVELS OF GLUTATHIONE | PHARMACIA ITALIA S.P.A. (IT) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092453-A1 | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites | HDGF, TUBB1, BCOR | ESR1 3539/4885ESR2 1737/4885TOP1 38/4885 |
| US-20030162722-A1 | Pharmaceutical compositions comprising acryloyl distamycin derivatives and topoisomerase I and II inhibitors | TOP2A, TOP1, TOP2B | ESR1 3510/4885ESR2 2241/4885TOP1 2/4885 |
| US-20090074757-A1 | Antitumor Combination Comprising Substituted Acryloyl Distamycin Derivatives and Antibodies Inhibiting Growth Factors or Their Receptors | HDGF, MET, HGF | ESR1 2554/4885ESR2 593/4885TOP1 1493/4885 |
| US-20030180383-A1 | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents | GSTM2, GSTP1, GSTA1 | ESR1 4231/4885ESR2 1528/4885TOP1 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.